This page shows the latest RVT-602 news and features for those working in and with pharma, biotech and healthcare.
Myovant has also received an exclusive, commercial license for RVT-602, Takeda's oligopeptide kisspeptin receptor agonist for the treatment of female infertility.
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
No results were found
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...